Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Author information

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. ladanyim@mskcc.org

Abstract

Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific cancers and these mutant proteins are proving to be excellent substrates for targeted therapies. This is the case for mutant EGFR-dependent lung adenocarcinomas, where EGFR mutation testing is already being used to help guide treatment decisions. Here, we provide an overview of the biology of EGFR-targeted therapies and the clinical experience to date, the positive and negative predictors of response, pathologic correlates of EGFR-mutant status, testing methods to establish patient eligibility for these agents, and the basis for primary and secondary resistance.

PMID:
18437168
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk